Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up billions in quarterly sales. Its only real competitor in weight management is ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...

Steroid dealers using social media and beauty salons to sell cheap Chinese copies of weight-loss drugs, experts warn ...

As the cost of Mounjaro jabs is set to increase by as much as 170 per cent, Jade Kay, who has already spent £2.4k on the drug ...